IGItai Ghersin

Itai Ghersin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Itai Ghersin has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk Factors for Post-Colonoscopy Colorectal Cancer in a Tertiary Medical Center: Root-Cause Analysis and a Case–Control Study

    by Maria Postnikov, Yuri Gorelik, Itai Ghersin, Polina Stein, Yaniv Zohar, Amir Klein, Barbara G. Silverman, Anath A. Flugelman, Elizabeth E. Half

    Background/Objectives: Colonoscopy is the gold standard for colorectal cancer (CRC) detection; however, post-colonoscopy CRC (PCCRC), defined by the World Endoscopy Organization (WEO) as CRC diagnosed 6–48 months after a negative colonoscopy, remains a clinical concern. This study aimed to identify risk factors and root causes associated with PCCRC at a large tertiary medical center. Methods: A retrospective analysis was performed of all colonoscopies conducted between 2001 and 2019. Data from electronic medical records were cross-referenced with the Israeli Cancer Registry. PCCRCs were defined per WEO criteria and independently verified by two physicians. Root-cause analysis classified cases as: (A) possible missed lesion with adequate index exam, (B) possible missed lesion with inadequate exam, (C) detected but unresected lesion, or (D) incomplete resection. PCCRCs were compared with colonoscopy-detected CRCs at a 1:3 ratio. Demographic, clinical, and endoscopic parameters were evaluated using multivariable logistic regression adjusted for age and sex. Mismatch repair (MMR) protein expression was assessed by immunohistochemistry and compared between PCCRC and control CRC cases (1:1 ratio). Results: Among 54,154 colonoscopies, 2,339 CRCs were diagnosed, including 49 (2.1%) PCCRCs. Missed lesions were the predominant cause: category A (59.1%) and B (34.6%). PCCRCs were mainly right-sided (49%) or rectal (24.5%). Factors independently associated with PCCRC included obesity (aOR = 3.00, 95% CI 1.32–6.88) and surveillance indication (aOR = 6.07, 95% CI 1.99–20.54), while abnormal imaging indication was inversely associated (aOR = 0.18, 95% CI 0.05–0.51). MMR analysis did not identify a significant difference between groups; however, the small sample size and technical limitations precluded definitive conclusions. Clear follow-up recommendations were not documented in 49% of PCCRC cases. Conclusions: Most PCCRCs stemmed from possible missed lesions. Obesity and surveillance as an indication were associated with increased PCCRC risk, while incomplete follow-up documentation may represent an opportunity for quality improvement. The exploratory MMR analysis was inconclusive, and further research is needed.

  • Open Access

    Dietary Management After Ulcerative Colitis Surgery: A Thematic Analysis of TikTok Content

    by Oliver R. Kaye, Dakota R. Rhys-Jones, Orestis Argyriou, Sue Blackwell, Emma P. Halmos, Zaid Ardalan, Janindra Warusavitarne, Kapil Sahnan, Jonathan P. Segal, Ailsa L. Hart, et al.

    Background/Objectives: For patients with Ulcerative Colitis (UC) requiring surgical treatment, post-operative dietary management can pose significant challenges. TikTok is emerging as a popular social media platform for dissemination of health and nutrition information. The aim of this study is to analyse patient-generated content on TikTok regarding dietary management post-UC surgery, in order to identify recurring themes and highlight patient priorities. Methods: Relevant TikTok videos were identified through a systematic search. Search terms were developed by combining ‘diet UC’ or ‘nutrition UC’ with common UC surgical procedures. From each search term, the first 10 videos were screened. If a search produced fewer than 10 results, all identified videos were retrieved. Inclusion criteria were videos in English, and a strong indication that the content creator was diagnosed with UC and had undergone relevant surgery, and was providing nutrition recommendations. Thematic analysis of video transcripts was conducted using Braun and Clarke’s framework to identify common themes. Results: A total of 89 videos, created between 2021 and 2024, were found on the initial search, of which 12 duplicates were removed, and 77 videos were screened. Sixteen English language videos met the inclusion criteria and were analysed. Thematic analysis identified three overarching themes: (1) adaptive dietary progression in the post-surgical period, where patients described a phased approach to reintroducing foods post-surgery; (2) personalisation of diet, highlighting individualised strategies for symptom and hydration management; and (3) Emotional and social impact of dietary restrictions and modifications, including fear of food and social isolation. Conclusions: This thematic analysis offers an insight into how patients navigate the complex management of diet following UC surgery. It is important for clinicians to discuss the dietary information and online content patients are exposed to in relation to their condition. Additionally, clinical practice should evolve to embrace patient-centred, multidisciplinary approaches that validate lived experience, ensure consistent dietary guidance, and address the psychological burden of dietary restriction.


  • Open Access

    A Pilot Study of the Effectiveness and Safety of Subcutaneous Infliximab in Chronic Inflammatory Pouch Conditions: The St. Mark’s Experience

    by Itai Ghersin, Orestis Argyriou, Kapil Sahnan, Janindra Warusavitarne, Ailsa L. Hart

    Background/Objectives: Infliximab (IFX) is commonly used in chronic inflammatory conditions of the ileo-anal pouch. A subcutaneous (SC) formulation has been developed, with studies in inflammatory bowel disease (IBD) patients showing that switching from intravenous (IV) to SC IFX is safe with a low risk of relapse. However, so far, it has not been specifically investigated in chronic inflammatory pouch conditions. The aim of our study was to evaluate the effectiveness and safety of SC IFX in patients with chronic inflammatory pouch conditions. Methods: This was an observational retrospective study. We included patients with chronic inflammatory pouch conditions, initially treated with IV IFX and subsequently switched to SC IFX, who had a follow-up of at least 1 year. The primary outcome was SC IFX treatment persistence, defined as continuation of SC IFX throughout the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy or pouch excision. Results: A total of seven patients were included. The mean age was 50.6 years. The average follow-up length was 101.3 months (range 70.4–132.6 months). All seven patients continued SC IFX throughout the study period. No patient experienced pouch failure. The median IFX serum concentration was 18.1 mg/L. There were no cases of serious infections or malignancy. Conclusions: Switching clinically stable patients with chronic inflammatory pouch conditions from IV to SC IFX formulation appears feasible. These findings warrant confirmation in larger patient cohorts.


  • Open Access

    The Rectal Stump During and After Subtotal Colectomy for Ulcerative Colitis: A Narrative Review of Surgical Strategies, Medical Management Options, and Cancer Surveillance Recommendations

    by Orestis Argyriou, Itai Ghersin, George Stravodimos, Guy Worley, Phil Tozer, Ailsa Hart, Kapil Sahnan

    Background/Objectives: There are multiple decision nodes, during and after subtotal colectomy for ulcerative colitis (UC), regarding the management of the rectal stump. Intra-operatively, the surgeon must decide on the closure technique and positioning of the retained stump, while post-operatively, clinicians often face the challenge of managing diversion proctitis, as well as determining an appropriate endoscopic surveillance strategy, given the increased risk of cancer. This narrative review aims to summarise the evidence relating to these key decision points in rectal stump management. Methods: A narrative review of the literature was performed. Relevant studies were identified through a search of Ovid Medline and Embase. Inclusion criteria were adult population and diagnosis of UC. Cohort studies, review articles, and guidelines were eligible for inclusion. The references were grouped according to the subject of interest and reported accordingly. Results: Intra-peritoneal closure has been shown to have higher pelvic sepsis rates (5–25%), whereas subcutaneous placement results in higher rates of wound infections (up to 15%). A mucous fistula has been shown to have the lowest overall complication rate. Microscopic findings compatible with diversion proctitis develop in most patients, with incidence ranging from 71.4% to 100%. However, only a minority of these patients (30–40%) develop symptoms. Suggested treatments for diversion proctitis include topical mesalamine, corticosteroids, or short-chain fatty acids. The overall risk of rectal stump neoplasia in patients with UC after subtotal colectomy is as low as 0.7%, with prior colorectal neoplasia being a major risk factor. No universal standardised guidance exists regarding endoscopic surveillance in this patient population. Conclusions: This narrative review has appraised the latest evidence on three crucial stages of rectal stump management in UC. There is still uncertainty about the optimal surgical management of the stump, with different complication profiles. Medical management of diversion proctitis remains a major unmet need, and there are no randomised trials addressing this issue. There are no universally accepted guidelines on endoscopic surveillance of the rectal stump.


  • Open Access

    Enhancing Patient Understanding of Perianal Fistula MRI Findings Using ChatGPT: A Randomized, Single Centre Study

    by Easan Anand, Itai Ghersin, Gita Lingam, Katie Devlin, Theo Pelly, Daniel Singer, Chris Tomlinson, Robin E. J. Munro, Rachel Capstick, Anna Antoniou, et al.

    Background/Objectives: Large Language Models (LLMs) may help translate complex Magnetic Resonance Imaging (MRI) fistula reports into accessible, patient-friendly summaries. This study evaluated the clinical utility, safety, and patient acceptability of Generative Pre-trained Transformer (GPT-4o) in generating such reports. Methods: A three-phase study was conducted at a single centre. Phase I involved prompt engineering and pilot testing of GPT-4o outputs for feasibility. Phase II assessed 250 consecutive MRI fistula reports from September 2024 to November 2024, each reviewed by a multi-disciplinary panel to determine hallucinations and thematic content. Phase III randomised patients to review either a simple or complex fistula case, each containing an original report and an Artificial Intelligence (AI)-generated summary (order randomised, origin blinded), and rate readability, trustworthiness, usefulness and comprehension. Results: Sixteen patients participated in Phase I pilot testing. In Phase II, hallucinations occurred in 11% of outputs, with unverified recommendations also identified. In Phase III, 61 patients (mean age 48, 41% female) evaluated paired original and AI-generated summaries. AI summaries scored significantly higher for readability, comprehension, and usefulness than original reports (all p < 0.001), with equivalent trust ratings. Mean Flesch-Kincaid scores were markedly higher for AI-generated summaries (66 vs. 26; p < 0.001). Clinicians highlighted improved anatomical structuring and accessible language, but emphasised risks of inaccuracies. A revised template incorporating Multi-Disciplinary Team (MDT)-focused action points and a lay summary section was co-developed. Conclusions: LLMs can enhance the readability and patient understanding of complex MRI reports but remain limited by hallucinations and inconsistent terminology. Safe implementation requires structured oversight, domain-specific refinement, and clinician validation. Future development should prioritise standardised reporting templates incorporating clinician-approved lay summaries.


  • Long‐term outcomes of biologic therapy for the treatment of prepouch ileitis: A multi‐centre multi‐national retrospective study

    by Itai Ghersin, Giacomo Calini, Eduard Koifman, Maya Fischman, Valerio Celentano, Jonathan P. Segal, Orestis Argyriou, Simon D. McLaughlin, Heather Johnson, Matteo Rottoli, et al.

    Aim: Prepouch ileitis (PPI) is inflammation of the ileum proximal to an ileoanal pouch, usually associated with pouchitis. The treatment of PPI as a specific entity is poorly studied, and long‐term follow‐up data are lacking. We aimed to describe the long‐term outcomes of biologic therapy in a large, multi‐centre, multi‐national cohort of patients with PPI. Methods: This was an observational, retrospective, multi‐centre, multi‐national study. We included patients with an endoscopic diagnosis of PPI, treated with biologic medications, who had a follow‐up of at least 1 year after biologic treatment initiation. The primary outcome was first‐line biologic treatment discontinuation during the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy and/or pouch excision. Results: There were 71 patients in our cohort. Average follow‐up length was 101.1 months (±54.5 months). Infliximab was first‐line treatment in 42 patients (59.2%), whereas 26 (36.6%) initially received Adalimumab and 3 (4.2%) received Vedolizumab treatment. At the end of the study period, only 16/71 patients (22.5%) were still on first‐line biologic treatment. Persistence rates for infliximab (7/42, 16.7%) and adalimumab (7/26, 26.9%) were similar ( p = 0.30). Out of 55 patients discontinuing first‐line biologic treatment, 26 (36.6% of the cohort) developed pouch failure, and 29 (40.8%) are currently treated with a different medication. Conclusion: First‐line biologic treatment for PPI is associated with high rates of treatment discontinuation. A significant proportion of PPI patients initially treated with biologics develop pouch failure.


  • Open Access

    AI-Generated Patient-Friendly MRI Fistula Summaries: A Pilot Randomised Study

    by Easan Anand, Itai Ghersin, Gita Lingam, Theo Pelly, Daniel Singer, Chris Tomlinson, Robin E. J. Munro, Rachel Capstick, Anna Antoniou, Ailsa L. Hart, et al.

    Perianal fistulising Crohn’s disease (pfCD) affects 1 in 5 Crohn’s patients and requires frequent MRI monitoring. Standard radiology reports are written for clinicians using technical language often inaccessible to patients, which can cause anxiety and hinder engagement. This study evaluates the feasibility and safety of AI-generated patient-friendly MRI fistula summaries to improve patient understanding and shared decision-making. MRI fistula reports spanning healed to complex disease were identified and used to generate AI patient-friendly summaries via ChatGPT-4. Six de-identified MRI reports and corresponding AI summaries were assessed by clinicians for hallucinations and readability (Flesch-Kincaid score). Sixteen patients with perianal fistulas were randomized to review either AI summaries or original reports and rated them on readability, comprehensibility, utility, quality, follow-up questions, and trustworthiness using Likert scales. Patients rated AI summaries significantly higher in readability (median 5 vs. 2, p = 0.011), comprehensibility (5 vs. 2, p = 0.007), utility (5 vs. 3, p = 0.014), and overall quality (4.5 vs. 4, p = 0.013), with fewer follow-up questions (3 vs. 4, p = 0.018). Clinicians found AI summaries more readable (mean Flesch-Kincaid 54.6 vs. 32.2, p = 0.005) and free of hallucinations. No clinically significant inaccuracies were identified. AI-generated patient-friendly MRI summaries have potential to enhance patient communication and clinical workflow in pfCD. Larger studies are needed to validate clinical utility, hallucination rates, and acceptability.


  • Open Access

    Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study

    by Itai Ghersin, Maya Fischman, Giacomo Calini, Eduard Koifman, Valerio Celentano, Jonathan P. Segal, Orestis Argyriou, Simon D. McLaughlin, Heather Johnson, Matteo Rottoli, et al.

    Background/Objectives: Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions. However, their use in these conditions is mainly based on retrospective studies of relatively small numbers of patients with short follow up periods. We aimed to describe the long-term outcomes of first-line anti-TNF therapy in a large, multi-centre, multi-national patient cohort with chronic inflammatory pouch conditions. Methods: This was an observational, retrospective, multi-centre, multi-national study. We included patients with chronic inflammatory pouch conditions initially treated with anti-TNF drugs infliximab (IFX) or adalimumab (ADA), who had a follow up of at least 1 year. The primary outcome was anti-TNF treatment persistence, defined as continuation of anti-TNF throughout the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy or pouch excision. Results: We recruited 98 patients with chronic inflammatory pouch conditions initially treated with anti-TNF medications—63 (64.3%) treated with IFX and 35 (35.7%) treated with ADA. Average follow up length was 94.2 months (±54.5). At the end of the study period only 22/98 (22.4%) patients were still on anti-TNF treatment. In those in whom the first-line anti-TNF was discontinued, the median time to discontinuation was 12.2 months (range 5.1–26.9 months). The most common cause for anti-TNF discontinuation was lack of efficacy despite adequate serum drug levels and absence of anti-drug antibody formation (30 patients, 30.6%). Loss of response due to anti-drug antibody formation was the cause for discontinuation in 18 patients (18.4%), while 12 patients (12.2%) stopped treatment because of adverse events or safety concerns. Out of the 76 patients discontinuing anti-TNF treatment, 34 (34.7% of the cohort) developed pouch failure, and 42 (42.8% of the cohort) are currently treated with a different medical therapy. Conclusions: First-line anti-TNF therapy for chronic pouch inflammatory conditions is associated with low long-term persistence rates. This is due to a combination of lack of efficacy and adverse events. A significant percentage of patients initially treated with anti-TNF therapy develop pouch failure.


  • Open Access

    A Quality Assessment and Evaluation of Credible Online Dietary Resources for Patients with an Ileoanal Pouch

    by Dakota R. Rhys-Jones, Itai Ghersin, Orestis Argyriou, Sue Blackwell, Jasmine Lester, Peter R. Gibson, Emma P. Halmos, Zaid Ardalan, Janindra Warusavitarne, Kapil Sahnan, et al.

    Background/Objectives: Patients with an ileoanal pouch change their diet to manage their symptoms and will often resort to the internet for nutrition advice. Currently, no evidence-based dietary guidelines exist to inform online resources. Hence, this study aims to assess the quality of online nutrition information directed towards patients with an ileoanal pouch. Methods: A systematic Google search was conducted to identify consumer websites including information on nutrition for those with ileoanal pouches. Quality was assessed using the DISCERN instrument, and the readability of written content was assessed using the Flesch–Kincaid score. A summative content analysis was used to identify the frequency of particular topics. Websites were also assessed against standards from the National Institute for Health and Care Excellence (NICE) framework for shared decision-making support tools. Results: A total of 12 websites met the inclusion criteria. Mean total DISCERN scores across all websites are 33 out of 75, indicating that overall, the websites were of poor quality. The mean Flesch–Kincaid score was 57 out of 100, or “fairly difficult” in terms of readability. The main themes according to the content analysis were “general dietary advice for pouch”, “dietary strategies for symptom management”, “addressing risks associated with having a pouch”, and “optimisation of nutritional intake”. Overall, websites did not meet the standards for shared decision-making. Conclusions: Online nutrition information for patients with an ileoanal pouch is of poor quality and difficult to understand. There is a need for higher quality online resources for these patients, ideally co-produced with a multidisciplinary team and patient, to provide patients with good quality, understandable, and accessible nutrition information.


  • Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis

    by Maya Fischman, Adi Elias, Amir Klein, Yaron Cohen, Zaher S. Azzam, Itai Ghersin

    Proton pump inhibitors (PPIs) decrease pancreatic exocrine secretions. There has been interest in the impact of their short‐term in‐hospital administration on acute pancreatitis (AP) outcomes. It is unknown whether long‐term use affects AP outcomes. We investigated the association between chronic PPI use and short‐term AP outcomes. We included all (2308) patients admitted with a primary diagnosis of AP (625 on chronic PPI use) between January 2008 and June 2021 and evaluated any association between chronic PPI use and 30‐day all‐cause mortality by univariate logistic regression. Compared to non‐users, patients on chronic PPIs were older (p < 0.001) and had a higher Charlson Comorbidity Index score (p < 0.001). Mortality rates at 30 days were 1.6% in chronic PPI users and 4.4% in non‐users (OR 0.35; 95% CI, 0.17–0.66; p < 0.002). [Correction added on 18 February 2025, after first online publication: Mortality rates at 30 days in chronic PPI users and non‐users were updated in this version.]